The Latest Breaking News from biotechnology

PDS Biotechnology Gains On FDA Fast Track Designation For Lead Candidate

The U.S.

Benzinga · Jun 2, 2022

Industrial biotechnology centre reopens innovation fund to new proposals

While any area of biotech will be considered for funding, it is particularly looking for projects focused on agriculture and food

Insider UK · May 27, 2022

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than its all-time high price ($174.79 vs. $66.50).

Benzinga · May 25, 2022

AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)

AstraZeneca plc (NASDAQ:AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ Biotechnology Ltd. In addition to the initial sum, AstraZeneca will pay possible royalty payments as part of the exclusive license to develop pre-clinical COVID antibodies engineered by RQ…

Benzinga · May 17, 2022

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

Benzinga · May 12, 2022

Recap: PDS Biotechnology Q1 Earnings

  PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 11, 2022

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB), considered a proxy for the sector, shed close to 3 percent during the week.

Benzinga · May 9, 2022

Biotechnology brains flock to regional Australia, but trials still based in metro areas

Much of Australia's biotech sector is based in regional Australia, but a lack of adequate, but a lack of adequate infrastructure means country patients are still missing out on the early stages of groundbreaking trials.

ABC News · May 9, 2022

Where Vir Biotechnology Stands With Analysts

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

Benzinga · May 6, 2022

Earnings Outlook For Vir Biotechnology

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.

Benzinga · May 4, 2022